The federal government is suing some big pharmacy benefit managers over a system of drug rebates that regulators say has made the price of insulin soar for diabetic patients.
The Federal Trade Commission is suing the three largest prescription drug benefit managers (PBMs) for allegedly driving up ...
The Federal Trade Commission's administrative complaint follows an interim report from the agency regarding PBM practices.